Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Lemonade

QuantumScape

Investing in unconventional stocks can be just as rewarding as investing in companies that are easy to comprehend.

The 3 Most Fascinating Stocks to Buy Now

Merck & Co (NYSE: MRK) has announced data from Phase 3 KEYNOTE-775/Study 309 trial evaluating Keytruda combined with Eisai Co Ltd's (OCTMKTS: ESALY) Lenvima for advanced, metastatic, or recurrent endometrial cancer following one prior platinum-based regimen in any setting. The data were presented at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.

Merck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Significantly Improved Progression-Free Survival and Overall Survival vs Chemo in Patients With Advanced Endometrial Cancer

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.

Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.

Germany's Merck KGaA (OTCMKT: MKGAF) will invest €25 million in its Molsheim, France facility to make disposable materials for bioreactors, an essential material required for COVID-19 vaccine manufacturing. The new site will see the creation of 350 jobs, along with 1,700 square meters of cleanrooms.

Germany's Merck Invests In French Facility For Single Use Products

Germany's Merck KGaA said it would invest 25 million euros ($29.9 million) in Molsheim, France, to make disposable plastic materials for bioreactors, an essential input for COVID-19 vaccine manufacturing.

Germany's Merck in fresh investment to make bioreactor gear in France

The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.

Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag

Privately-held Amathus Therapeutics has entered into a strategic collaboration with Merck & Co (NYSE: MRK) to develop novel small molecule therapeutic candidates for neurodegenerative diseases. Under the terms of the agreement, Amathus will be responsible for identifying and progressing novel chaperone activators through preclinical discovery.

Amathus Therapeutics, Merck In Agreement For Neurodegenerative Disease-Targeted Therapies

Merck & Co said on Wednesday its Chief Marketing Officer Michael Nally will leave the company, the second top executive to do so after the drugmaker announced last month its Chief Executive Officer Kenneth Frazier will step down in June.

Merck's marketing executive Michael Nally to step down

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves Expanded Indication for KEYTRUDA in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

European Commission Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Mike Nally to leave Merck; Frank Clyburn to lead all Merck Human Health

Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health

AbbVie

Eli Lilly

Pfizer

An easily overlooked provision in the legislation could be bad news for four drugmakers, in particular.

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

The FDA has granted Priority Review designation to Merck & Co (NYSE: MRK) Belzutifan, formerly known as PT2977. The drug candidate was considered the centerpiece in Merck's 2019 over $1billion buyout of Peloton Therapeutics.

Merck's Belzutifan Wins Priority Review Status In Type Of Kidney Cancer

Gilead Sciences

Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.

Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments

Immutep Ltd

Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients.

Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer Study

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)

Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)

Not intended for UK-based media   DARMSTADT, Germany, March 16, 2021 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy. In the study of 159 patients, bintrafusp alfa demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up, with an Independent Review Committee (IRC)-adjudicated objective response rate (ORR) of 10.1% (95% CI: 5.9% to 15.8%) per RECIST 1.1.

Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Gilead Sciences and Merck inked a deal Monday to co-develop a combined HIV treatment, sending Gilead stock and Merck stock higher. The deal has been long-anticipated by investors.

Gilead, Merck Hook Up In Long-Anticipated HIV Drug Deal, Stoking Shares

Merck is a leading company in the healthcare business. The company has strong fundamentals, low valuation, and one major-specific challenge.

Merck: When Cash Flow Meets Valuation

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead

Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead

FOSTER CITY, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead's investigational capsid inhibitor, lenacapavir, and Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Apple

Salesforce

Walmart

The world's most iconic stock index is housing some serious bargains.

4 Dow Stocks With 24% to 31% Upside, According to Wall Street

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

This is Why Merck (MRK) is a Great Dividend Stock

Agree Realty

Crown Castle International

iShares Select Dividend ETF

NextEra Energy

QTS Realty Trust

Schwab US Dividend Equity ETF

SPDR S&P Dividend ETF

Vanguard Dividend Appreciation ETF

There are two primary styles of investing that attract Millennials to the stock market. One of these investing styles is FIRE, an acronym that stands for "Financial Independence, Retire Early."

Investing For FIRE? Dividend Growth Is The Way To Go

Merck's (MRK) Management on Barclays Global Healthcare Conference

News for Merck Stock (MRK)